Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide in pediatric secondary hyperparathyroidism on hemodialysis
2018-004608-21Phase 3Active
- Sponsor
- Amgen
- Start
- Jun 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Percent change in intact parathyroid hormone from baseline. Started Jun 2019; status: active.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on 2018-004608-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004608-21.